Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia

Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia

Background: It would be clinically useful to prospectively identify the risk of disease progression in chronic myeloid leukaemia (CML). Overexpression of cancerous inhibitor of protein phosphatase 2A (PP2A) (CIP2A) protein is an adverse prognostic indicator in many cancers. Methods: We examined CIP2...

Full description

Bibliographic Details
Main Authors: Richard E. Clark, Ammar A. Basabrain, Gemma M. Austin, Alison K. Holcroft, Sandra Loaiza, Jane F. Apperley, Christopher Law, Laura Scott, Alexandra D. Parry, Laura Bonnett, Claire M. Lucas
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
CIP2A
CML
blast crisis
imatinib
dasatinib
SPIRIT2
Online Access:https://www.mdpi.com/2072-6694/13/9/2155

Internet

https://www.mdpi.com/2072-6694/13/9/2155

Similar Items